A review of key relevant data on HER2-positive breast cancer from the 2020 SABCS Virtual Symposium.
EP. 1: 2020 in Review: HER2+ Breast Cancer
Experts in breast oncology discuss the evolving landscape in early stage and metastatic HER2-positive breast cancer.
EP. 2: HER2+ BC: Unanswered Questions in Sequencing
Andrew Seidman, MD, provides insight on clinical sequencing for patients with advanced HER2-positive breast cancer.
EP. 3: Predictive Biomarkers: HER2-Enriched Subtypes
Hatem Soliman, MD, discusses data presented at the 2020 SABCS for patients with HER2-enriched subtypes that showed benefit from CDK4/6 inhibition.
EP. 4: Prognostic Tools for Early Stage BC
A discussion on the importance of prognostic tools for early stage breast cancer.
EP. 5: SABCS 2020 Updates: ExteNET and CONTROL Trials
Updated findings on the use of neratinib for HER2+ breast cancer from the 2020 SABCS Virtual Symposium.
EP. 6: De-escalation in Neoadjuvant Setting for HER2+ BC
EP. 7: Disease-Free Interval and Overall Survival in HER2+ BC
Analysis from the ALTTO (BIG 2-06) trial and the relationship between a short or long disease-free interval and overall survival.
EP. 8: Ongoing Role of TDM-1 in Metastatic Breast Cancer
Experts in breast oncology discuss their real-world experience with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer.
EP. 9: SABCS 2020: PERTAIN Updates in HER2+, HR+ MBC
Hatem Soliman, MD, reviews statistically significant data from the PERTAIN study, presented at the 2020 San Antonio Breast Cancer Symposium.
EP. 10: Promising Data for Trastuzumab Deruxtecan Combination
Experts in breast oncology discuss the evolving role of trastuzumab deruxtecan for metastatic HER2-positive breast cancer.
EP. 11: SABCS 2020 Wrap-Up
Final analysis of data on HER2-positive disease presented at the 2020 San Antonio Breast Cancer Symposium from experts in the field of breast oncology.
2 Clarke Drive Cranbury, NJ 08512